Results 101 to 110 of about 22,351 (243)

Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study

Iranian Journal of Allergy, Asthma and Immunology, 2018
Fingolimod is a novel immunomodulatory drug used in patients with relapsing multiple sclerosis (MS) which reversibly inhibits egress of lymphocytes from lymph nodes. In this longitudinal study, the frequency of Interferon- gamma (IFN-γ)+, IL4+, IL17+ and
Bahare Laribi, Mohammad Ali Sahraian, Mehdi Shekarabi, Rahimeh Emamnejad, Mohsen Marzban, Shokufeh Sadaghiani, Maryam Izad   +6 more
doaj   +1 more source

Real‐World Safety and Effectiveness of Glatiramer Acetate in Patients With Multiple Sclerosis: Final Results of Post‐Marketing Surveillance in Japan

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Background Glatiramer acetate is an injectable disease‐modifying therapy indicated for multiple sclerosis (MS). Aim To evaluate the real‐world safety and effectiveness of glatiramer acetate for MS in Japan. Methods A prospective, multicenter, observational, all‐case post‐marketing survey was conducted in Japan between November 2015 and March ...
Masaaki Niino, Eriko Hayashi, Mai Itani, Jun‐ichi Kira   +3 more
wiley   +1 more source

The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of patients with relapsing forms of multiple sclerosis (RMS).
Jeffrey A Cohen, Amit Bar-Or, Bruce A C Cree, Yang Mao-Draayer, May H Han, Barry Singer, Ann Jannu, Scott Kolodny, Xiangyi Meng, Ryan C Winger   +9 more
doaj   +1 more source

Sphinganine‐phosphate prevents influenza infection via promoting CD8+ T cells proliferation and activation

VIEW, EarlyView.
This study established clinical cohorts of respiratory viral infections and identified sphinganine‐phosphate (SA) as a metabolite significantly upregulated post‐infection through metabolomic analysis. In vitro and in vivo experiments demonstrated that SA promotes the generation of effector CD8+ T cells via the SOCS1/JAK1/STAT1 pathway, which ...
Zhongwen Hu, Guiling Yan, Junhong Li, Yuan Yuan, Hong Zhang, Yuchao Zhong, Yuanyuan Peng, Wenjia Zhang, Xiaoyan Su, Changchun Niu, Yang Luo   +10 more
wiley   +1 more source

The effects of fingolimod and fingolimod-phosphate on BMECs.

, 2015
(A) The effects of fingolimod and fingolimod-phosphate on tight junction proteins, such as claudin-5 and occludin, and adhesion molecules, including ICAM-1 and MelCAM, in the human brain microvascular endothelial cells (BMECs) were measured using a ...
Fumitaka Shimizu (545145), Toshihiko Maeda (702834), Masaaki Abe (202786), Yasuteru Sano (545147), Michiaki Koga (60773), Takashi Kanda (545152), Yukio Takeshita (702833), Hideaki Nishihara (545149)   +7 more
core   +1 more source

Fingolimod after natalizumab and the risk of short-term relapse

, 2014
OBJECTIVE: To determine early risk of relapse after switch from natalizumab to fingolimod; to compare the switch experience to that in patients switching from interferon-β/glatiramer acetate (IFN-β/GA) and those previously treatment naive; and to ...
C Boz (13311711), M Barnett (13287606), DLA Spitaleri (14466246), S Hodgkinson (13311777), J Lechner-Scott (13311723), VG Jokubaitis (14466183), T Kalincik (10539092), M Slee (13311747), M Girard (13311678), G Giuliani (11140461), P Duquette (13311681), M Trojano (13311672), F Verheul (13461012), A Lugaresi (13311687), D Liew (9853673), F Grand'Maison (13311690), R Alroughani (13311708), Cameron Shaw (13094307), V Li (13455537), G Izquierdo (10697262)   +19 more
core   +2 more sources

Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.

PLoS ONE, 2020
PurposeThe objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice.MethodsThis observational, retrospective ...
Francisco Barrero, Javier Mallada-Frechin, María Luisa Martínez-Ginés, María Eugenia Marzo, Virginia Meca-Lallana, Guillermo Izquierdo, José Ramón Ara, Celia Oreja-Guevara, José Meca-Lallana, Lucía Forero, Irene Sánchez-Vera, María José Moreno, in representation of the MS NEXT study investigators   +12 more
doaj   +1 more source

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Annals of Neurology, 2020
Novel, highly effective disease‐modifying therapies have revolutionized multiple sclerosis (MS) care. However, evidence from large comparative studies on important safety outcomes, such as cancer, is still lacking.
Peter Alping, J. Askling, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell   +15 more
semanticscholar   +1 more source

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population

ARYA Atherosclerosis, 2017
BACKGROUND: Fingolimod (FTY-720) has shown efficacy in relapsing multiple sclerosis (MS), while some side effects of this drug have been recognized that the most important is cardiovascular side effects.
Morteza Abdar, Payam Ebrahimifar, Masoud Etemadifar   +2 more
doaj  

Cost minimisation analysis of fingolimod vs. natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2014
Introduction: At present, there is a lack of economic assessments of second-line treatments for relapsing-recurring multiple sclerosis. The aim of this study was to compare the efficiency between fingolimod and natalizumab in Spain.
C. Crespo, G. Izquierdo, A. García-Ruiz, M. Granell, M. Brosa   +4 more
doaj   +1 more source